{"id":"NCT00258154","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010)","officialTitle":"Safety and Immunogenicity of Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-02","primaryCompletion":"2006-11","completion":"2006-11","firstPosted":"2005-11-24","resultsPosted":"2009-09-23","lastUpdate":"2015-10-06"},"enrollment":403,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rotavirus Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Rotavirus Vaccine, Live, Oral, Pentavalent","otherNames":[]},{"type":"BIOLOGICAL","name":"Comparator: placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"Comparator: Infanrix(tm) Hexa","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The study is being conducted to demonstrate that the vaccine to prevent gastroenteritis due to rotavirus may be administered concomitantly with INFANRIX(tm)hexa without impairing the safety and immunogenicity of either vaccine.","primaryOutcome":{"measure":"Immunogenicity of INFANRIX™ Hexa in Relation to Anti-hepatitis B Surface Antigen HBsAg, Predose 1","timeFrame":"Day 1 of a 3-dose regimen","effectByArm":[{"arm":"RotaTeq™ + INFANRIX Hexa","deltaMin":12.7,"sd":null},{"arm":"Placebo + INFANRIX Hexa","deltaMin":13.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":18},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["19209092"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":201},"commonTop":["Pyrexia","Diarrhoea","Vomiting","Enteritis","Rhinitis"]}}